101,773 Shares in ClearPoint Neuro, Inc. (NASDAQ:CLPT) Bought by Squarepoint Ops LLC

Squarepoint Ops LLC bought a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 101,773 shares of the company’s stock, valued at approximately $549,000. Squarepoint Ops LLC owned about 0.37% of ClearPoint Neuro at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in CLPT. Cubist Systematic Strategies LLC bought a new stake in shares of ClearPoint Neuro in the second quarter valued at approximately $419,000. Point72 DIFC Ltd acquired a new stake in ClearPoint Neuro in the 2nd quarter worth $32,000. Marshall Wace LLP grew its position in ClearPoint Neuro by 202.2% in the 2nd quarter. Marshall Wace LLP now owns 58,260 shares of the company’s stock worth $314,000 after purchasing an additional 38,984 shares during the last quarter. XTX Topco Ltd raised its position in shares of ClearPoint Neuro by 11.6% during the second quarter. XTX Topco Ltd now owns 13,010 shares of the company’s stock valued at $70,000 after buying an additional 1,353 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of ClearPoint Neuro by 562.6% in the second quarter. Renaissance Technologies LLC now owns 169,700 shares of the company’s stock valued at $915,000 after buying an additional 144,088 shares during the period. 30.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. B. Riley assumed coverage on ClearPoint Neuro in a research note on Thursday, July 25th. They set a “buy” rating and a $10.00 price target on the stock. Lake Street Capital upped their target price on ClearPoint Neuro from $11.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th.

ClearPoint Neuro Stock Up 7.6 %

NASDAQ CLPT opened at $11.62 on Wednesday. ClearPoint Neuro, Inc. has a twelve month low of $4.05 and a twelve month high of $13.47. The stock has a market cap of $318.62 million, a P/E ratio of -13.83 and a beta of 1.10. The company’s 50-day simple moving average is $10.96 and its 200 day simple moving average is $7.80.

ClearPoint Neuro (NASDAQ:CLPT) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. ClearPoint Neuro had a negative return on equity of 64.23% and a negative net margin of 64.06%. The company had revenue of $7.86 million for the quarter, compared to analyst estimates of $7.50 million. During the same period in the prior year, the company posted ($0.29) EPS. Research analysts anticipate that ClearPoint Neuro, Inc. will post -0.65 earnings per share for the current year.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.